MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.
GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.
Bonum Therapeutics is a biopharmaceutical company focused on developing innovative protein-based drugs designed to treat various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs with regulated, context-dependent activity. These drugs are engineered to sense their local environment and transition from an inactive to an active form, allowing for targeted therapeutic effects. In addition to cancer, Bonum Therapeutics also aims to address metabolic diseases, immunological conditions, and pain management, thereby expanding its potential impact across multiple therapeutic areas.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.
Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, focuses on developing innovative immunotherapies for cancer treatment. The company is creating a new generation of conditionally active bispecific T-cell engaging antibodies specifically aimed at treating solid tumors. Utilizing its advanced T-LITE™ platform, Soteria enables small molecule-dependent activation of these bispecific antibody therapies, which facilitates safer and more effective treatment options. This approach allows for pulsatile activity, resulting in reduced side effects and the potential for higher dosing, thereby improving the overall therapeutic experience for patients.
Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.
Entrada Therapeutics, Inc. is a biotechnology company focused on treating diseases through the intracellular delivery of biologics, such as proteins, peptides, and nucleic acids. Founded in 2016 and based in Boston, Massachusetts, the company aims to transform patient care by developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible. Entrada's technology addresses challenges associated with delivering both large and small molecules, significantly enhancing the efficiency of therapeutic delivery into the cytosol. Its pipeline includes innovative therapies for neuromuscular diseases and other conditions, utilizing proprietary Endosomal Escape Vehicle (EEV) therapeutics to improve treatment outcomes across various organs and tissues.
Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.
Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing small molecule therapies aimed at improving patients' lives. Founded in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a discovery process that integrates clinically validated biological targets with advanced chemistry to create innovative oncology therapeutics. Enliven's product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and combat wild-type HER2. The company's therapeutic programs address critical challenges in oncology, such as tolerability, resistance, and disease escape, particularly in patients with brain metastases.
Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease. The company was founded in 2015 and headquartered in Horsham, Pennsylvania.
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.
Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.
Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
Purigen Biosystems, Inc. specializes in the manufacture of an ionic purification system aimed at the extraction and purification of nucleic acids from biological samples. Utilizing isotachophoresis, a technique that employs electric fields for the separation and purification of nucleic acids, the company offers an innovative solution that is agnostic to nucleic acid size or sequence. This technology is particularly effective for challenging sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues and low cell counts. Purigen's automated platform processes various biological samples such as mammalian cells, tissue biopsies, plasma, blood, and buccal swabs, delivering ready-to-use DNA or RNA for applications like qPCR, microarray, and next-generation sequencing (NGS) preparations. Founded in 2012 and based in Pleasanton, California, Purigen operates as a subsidiary of Agilent Technologies, providing researchers with a fast and efficient alternative for nucleic acid purification.
Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.
MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order to prevent vision loss.
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.
Entrada Therapeutics, Inc. is a biotechnology company focused on treating diseases through the intracellular delivery of biologics, such as proteins, peptides, and nucleic acids. Founded in 2016 and based in Boston, Massachusetts, the company aims to transform patient care by developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible. Entrada's technology addresses challenges associated with delivering both large and small molecules, significantly enhancing the efficiency of therapeutic delivery into the cytosol. Its pipeline includes innovative therapies for neuromuscular diseases and other conditions, utilizing proprietary Endosomal Escape Vehicle (EEV) therapeutics to improve treatment outcomes across various organs and tissues.
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
BlueLight Therapeutics Inc. is a protein analysis company based in South San Francisco, California, focused on developing products and systems to analyze real-time protein function for research and clinical applications. Utilizing proprietary second-harmonic generation technology, the company detects conformational changes in proteins and other biological molecules. Its flagship product, the Biodesy Delta System, allows researchers to measure functionally and clinically relevant alterations in protein structure. The company's applications span drug discovery, structural biology, and clinical biomarkers. Additionally, BlueLight Therapeutics employs a structure-based platform to discover small molecules targeting difficult-to-drug proteins, aiming to develop novel therapeutic solutions against high-value drug targets. Founded in 2013 and formerly known as Biodesy, Inc., the company rebranded in May 2020 to reflect its commitment to innovative therapeutic development.
Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on addressing significant unmet medical needs by creating distinct therapies that improve clinical care. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing the quality of life for patients, families, and caregivers.
Care Innovations specializes in technology-based healthcare management services that facilitate connections between individuals and caregivers. The company focuses on collecting, aggregating, and analyzing data to deliver actionable insights that bridge the gap between healthcare providers, payers, caregivers, and consumers. By enabling a seamless care continuum within the home, Care Innovations supports individuals in maintaining their independence while also aiming to reduce overall healthcare costs.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
CiVi Biopharma is a clinical stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development including Intravenous Iloprost in Phase 3 trials for treatment of Systemic Sclerosis.
Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.
Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.
Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.
Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.
Viewics, Inc. specializes in providing Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare sector in the United States and Canada. The company offers the Viewics Data Platform, which connects to various enterprise systems and accepts data in multiple formats for comprehensive analysis. Its flagship product, Viewics Health Insighter, delivers interactive dashboards for clinical, operational, sales, and marketing teams, facilitating informed decision-making. Additionally, Viewics Pulse serves as a web-based platform for data transparency and sharing among clients, patients, payors, and providers. The company’s solutions support clinical laboratories, pathology groups, blood banks, pharmacies, and hospitals, enabling them to gain insights into operational performance, financial management, and compliance. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG, focusing on empowering healthcare organizations with actionable data insights while alleviating the challenges faced by IT departments.
Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.
Purigen Biosystems, Inc. specializes in the manufacture of an ionic purification system aimed at the extraction and purification of nucleic acids from biological samples. Utilizing isotachophoresis, a technique that employs electric fields for the separation and purification of nucleic acids, the company offers an innovative solution that is agnostic to nucleic acid size or sequence. This technology is particularly effective for challenging sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues and low cell counts. Purigen's automated platform processes various biological samples such as mammalian cells, tissue biopsies, plasma, blood, and buccal swabs, delivering ready-to-use DNA or RNA for applications like qPCR, microarray, and next-generation sequencing (NGS) preparations. Founded in 2012 and based in Pleasanton, California, Purigen operates as a subsidiary of Agilent Technologies, providing researchers with a fast and efficient alternative for nucleic acid purification.
Lumos Pharma, based in Austin, Texas, is an early-stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency. It was founded in 2014 and is headquartered in Austin, Texas.
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
BlueLight Therapeutics Inc. is a protein analysis company based in South San Francisco, California, focused on developing products and systems to analyze real-time protein function for research and clinical applications. Utilizing proprietary second-harmonic generation technology, the company detects conformational changes in proteins and other biological molecules. Its flagship product, the Biodesy Delta System, allows researchers to measure functionally and clinically relevant alterations in protein structure. The company's applications span drug discovery, structural biology, and clinical biomarkers. Additionally, BlueLight Therapeutics employs a structure-based platform to discover small molecules targeting difficult-to-drug proteins, aiming to develop novel therapeutic solutions against high-value drug targets. Founded in 2013 and formerly known as Biodesy, Inc., the company rebranded in May 2020 to reflect its commitment to innovative therapeutic development.
Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on addressing significant unmet medical needs by creating distinct therapies that improve clinical care. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing the quality of life for patients, families, and caregivers.
MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order to prevent vision loss.
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
Stratos Genomics, Inc. is a Seattle-based company focused on advancing DNA sequencing technology. Founded in 2007, it specializes in a method known as sequencing by expansion, which employs single-molecule detection for genome sequencing and targeted oncology panels. The technology utilizes nanopore systems to identify unique electrical signals associated with each DNA base, facilitating precise and efficient sequencing. Stratos Genomics aims to establish a new standard in DNA sequencing by providing a low-cost, high-fidelity approach that enhances accessibility for scientists and clinicians. As of May 2020, Stratos Genomics operates as a subsidiary of Roche Holding AG.
mySugr GmbH is a digital health company focused on diabetes management, operating primarily in the United States and European Union. Founded in 2012 and based in Vienna, Austria, mySugr develops comprehensive solutions to assist individuals with diabetes. The mySugr App serves as a central tool that automatically logs blood sugar levels, carbohydrate intake, insulin doses, and activity data, integrating seamlessly with various connected medical devices. Additionally, the company offers features such as the mySugr Scanner for transferring glucose readings directly into the app, mySugr Academy for educational resources on type 2 diabetes, and mySugr Analysis for identifying trends in health data. With a commitment to empowering users through self-management, mySugr also provides unlimited test strips and coaching services, enhancing the overall support for diabetes management. The company operates as a subsidiary of Roche Holding AG since June 2017.
Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.
AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.
CytomX Therapeutics is an oncology-focused biopharmaceutical company based in South San Francisco, California. The company specializes in developing proteolytically-activated antibody therapeutics using its proprietary Probody technology platform. This innovative approach aims to create cancer immunotherapies that enhance targeting of tumor cells while minimizing effects on healthy tissues. CytomX's clinical-stage product candidates include CX-072, which targets programmed cell death ligand 1; CX-2009, a drug conjugate against CD166; and BMS-986249, a CTLA-4 Probody therapeutic for metastatic melanoma, among others. The company has established strategic collaborations with several major pharmaceutical companies, including AbbVie, Amgen, and Bristol-Myers Squibb, to further the development of its Probody therapeutics. Founded in 2008, CytomX is dedicated to providing patients with more effective and less toxic treatment options for cancer and inflammatory diseases.
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Aileron Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development of a novel class of therapeutics known as Stapled Peptides. These peptides are designed to modulate intracellular protein-protein interactions, which are essential for various cellular functions. The company's lead product candidate, ALRN-6924, is a chemoprotective agent aimed at treating advanced solid tumors, peripheral T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. Currently, ALRN-6924 is undergoing several clinical trials to evaluate its efficacy and safety in these conditions. Additionally, Aileron is developing other product candidates, such as LTI-03 and LTI-01, focused on fibrosis indications, while also advancing next-generation therapies that reactivate wild type p53. The company has established collaborations for clinical trials with prominent institutions, enhancing its research capabilities and potential impact in oncology.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Stratos Genomics, Inc. is a Seattle-based company focused on advancing DNA sequencing technology. Founded in 2007, it specializes in a method known as sequencing by expansion, which employs single-molecule detection for genome sequencing and targeted oncology panels. The technology utilizes nanopore systems to identify unique electrical signals associated with each DNA base, facilitating precise and efficient sequencing. Stratos Genomics aims to establish a new standard in DNA sequencing by providing a low-cost, high-fidelity approach that enhances accessibility for scientists and clinicians. As of May 2020, Stratos Genomics operates as a subsidiary of Roche Holding AG.
Alios BioPharma is focused on the discovery and development of innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company employs a range of proprietary technologies, including small molecule activators that stimulate innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons. These complementary platforms enable the development of various therapeutic products targeting serious viral infections, such as chronic hepatitis B and C, HIV, respiratory viruses like pandemic influenza, and emerging viral diseases such as SARS. Alios BioPharma’s unique chemical library of nucleoside analogs and advanced virology-based screening systems further enhance its ability to create effective antiviral agents.
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Aileron Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development of a novel class of therapeutics known as Stapled Peptides. These peptides are designed to modulate intracellular protein-protein interactions, which are essential for various cellular functions. The company's lead product candidate, ALRN-6924, is a chemoprotective agent aimed at treating advanced solid tumors, peripheral T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. Currently, ALRN-6924 is undergoing several clinical trials to evaluate its efficacy and safety in these conditions. Additionally, Aileron is developing other product candidates, such as LTI-03 and LTI-01, focused on fibrosis indications, while also advancing next-generation therapies that reactivate wild type p53. The company has established collaborations for clinical trials with prominent institutions, enhancing its research capabilities and potential impact in oncology.
BlueLight Therapeutics Inc. is a protein analysis company based in South San Francisco, California, focused on developing products and systems to analyze real-time protein function for research and clinical applications. Utilizing proprietary second-harmonic generation technology, the company detects conformational changes in proteins and other biological molecules. Its flagship product, the Biodesy Delta System, allows researchers to measure functionally and clinically relevant alterations in protein structure. The company's applications span drug discovery, structural biology, and clinical biomarkers. Additionally, BlueLight Therapeutics employs a structure-based platform to discover small molecules targeting difficult-to-drug proteins, aiming to develop novel therapeutic solutions against high-value drug targets. Founded in 2013 and formerly known as Biodesy, Inc., the company rebranded in May 2020 to reflect its commitment to innovative therapeutic development.
Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.
Horizon Discovery Group is a life science company based in Cambridge, United Kingdom, specializing in gene editing and gene modulation technologies. The company focuses on designing, manufacturing, and applying these tools across various sectors, including academic research, biopharmaceuticals, and diagnostics. Horizon offers a wide range of products and services, including custom and off-the-shelf RNAi and CRISPR reagents, cell models, and gene-edited CHO cells. Their extensive catalogue, which contains over 1,000,000 products, aids researchers in studying genetic anomalies associated with diseases such as cancer. Horizon also provides screening services, including pooled and arrayed CRISPR and RNAi screens, as well as custom cell engineering services. The company collaborates with various institutions to enhance its offerings and advance research in genetic editing technologies. Founded in 2007, Horizon Discovery operates internationally and sells its products through direct sales and e-commerce. As of late 2020, it became a subsidiary of PerkinElmer (UK) Holdings Ltd.
Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.
MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order to prevent vision loss.
Aileron Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development of a novel class of therapeutics known as Stapled Peptides. These peptides are designed to modulate intracellular protein-protein interactions, which are essential for various cellular functions. The company's lead product candidate, ALRN-6924, is a chemoprotective agent aimed at treating advanced solid tumors, peripheral T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. Currently, ALRN-6924 is undergoing several clinical trials to evaluate its efficacy and safety in these conditions. Additionally, Aileron is developing other product candidates, such as LTI-03 and LTI-01, focused on fibrosis indications, while also advancing next-generation therapies that reactivate wild type p53. The company has established collaborations for clinical trials with prominent institutions, enhancing its research capabilities and potential impact in oncology.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Foundation Medicine, Inc. specializes in providing molecular information products that enhance cancer treatment by utilizing advanced genomic profiling techniques. The company's platform analyzes various cancer specimens to deliver personalized genomic insights, which assist physicians in optimizing treatment plans and support biopharmaceutical companies in developing targeted therapies and immunotherapies. Key clinical products include FoundationOne, which focuses on solid tumors, and FoundationOne Heme for blood-based cancers. Additionally, Foundation Medicine offers diagnostic assays such as Foundation Assay for Circulating Tumor and FoundationFocus CDxBRCA, aimed at identifying ovarian cancer in women. The company maintains collaborative agreements with major pharmaceutical firms and organizations, such as F. Hoffmann-La Roche Ltd. and the European Organisation for Research and Treatment of Cancer, to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine is a subsidiary of Roche Holdings, Inc.
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Horizon Discovery Group is a life science company based in Cambridge, United Kingdom, specializing in gene editing and gene modulation technologies. The company focuses on designing, manufacturing, and applying these tools across various sectors, including academic research, biopharmaceuticals, and diagnostics. Horizon offers a wide range of products and services, including custom and off-the-shelf RNAi and CRISPR reagents, cell models, and gene-edited CHO cells. Their extensive catalogue, which contains over 1,000,000 products, aids researchers in studying genetic anomalies associated with diseases such as cancer. Horizon also provides screening services, including pooled and arrayed CRISPR and RNAi screens, as well as custom cell engineering services. The company collaborates with various institutions to enhance its offerings and advance research in genetic editing technologies. Founded in 2007, Horizon Discovery operates internationally and sells its products through direct sales and e-commerce. As of late 2020, it became a subsidiary of PerkinElmer (UK) Holdings Ltd.
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Horizon Discovery Group is a life science company based in Cambridge, United Kingdom, specializing in gene editing and gene modulation technologies. The company focuses on designing, manufacturing, and applying these tools across various sectors, including academic research, biopharmaceuticals, and diagnostics. Horizon offers a wide range of products and services, including custom and off-the-shelf RNAi and CRISPR reagents, cell models, and gene-edited CHO cells. Their extensive catalogue, which contains over 1,000,000 products, aids researchers in studying genetic anomalies associated with diseases such as cancer. Horizon also provides screening services, including pooled and arrayed CRISPR and RNAi screens, as well as custom cell engineering services. The company collaborates with various institutions to enhance its offerings and advance research in genetic editing technologies. Founded in 2007, Horizon Discovery operates internationally and sells its products through direct sales and e-commerce. As of late 2020, it became a subsidiary of PerkinElmer (UK) Holdings Ltd.
CytomX Therapeutics is an oncology-focused biopharmaceutical company based in South San Francisco, California. The company specializes in developing proteolytically-activated antibody therapeutics using its proprietary Probody technology platform. This innovative approach aims to create cancer immunotherapies that enhance targeting of tumor cells while minimizing effects on healthy tissues. CytomX's clinical-stage product candidates include CX-072, which targets programmed cell death ligand 1; CX-2009, a drug conjugate against CD166; and BMS-986249, a CTLA-4 Probody therapeutic for metastatic melanoma, among others. The company has established strategic collaborations with several major pharmaceutical companies, including AbbVie, Amgen, and Bristol-Myers Squibb, to further the development of its Probody therapeutics. Founded in 2008, CytomX is dedicated to providing patients with more effective and less toxic treatment options for cancer and inflammatory diseases.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.
Envoy Therapeutics focuses on drug discovery with the aim of developing new medications that demonstrate improved efficacy and reduced side effects compared to existing treatments. Utilizing its innovative bacTRAP® technology, the company identifies proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This capability is particularly significant in brain tissues, where numerous cell types are closely intermingled. By allowing for the targeted modulation of specific cell types based on their unique protein expression, Envoy Therapeutics enhances the possibilities for therapeutic interventions, marking a significant advancement in the field of drug discovery.